(Q36677407)

15 August 2017

1 reference

title

VEGF/VEGFR signalling as a target for inhibiting angiogenesis (English)

1 reference

15 August 2017

1 reference

Alex Kiselyov

1

1 reference

15 August 2017

Konstantin V Balakin

series ordinal

2

1 reference

15 August 2017

Sergey E Tkachenko

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

1 reference

15 August 2017

16

1 reference

15 August 2017

1

1 reference

15 August 2017

83-107

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

15 August 2017

1 reference

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

21 January 2018

Molecular angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Structure and function of placental growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor receptor family genes: when did the three genes phylogenetically segregate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Regulation of angiogenesis by hypoxia: role of the HIF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Growth factor signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Cell signalling: growth factors and tyrosine kinase receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Activation of STAT3 signaling in human stomach adenocarcinoma drug-resistant cell line and its relationship with expression of vascular endothelial growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Targeting VEGF in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Antisense oligonucleotide treatments for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Angiogenesis and remodeling of airway vasculature in chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor enhances atherosclerotic plaque progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Functional interaction of VEGF-C and VEGF-D with neuropilin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Angiogenesis as a target for tumor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

VEGF inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Monoclonal antibody strategies to block angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

In vitro selection of RNA molecules that bind specific ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Nucleic Acid Aptamers as Tools and Drugs: Recent Developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Aptamers: an emerging class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Hammerhead ribozyme engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Non-viral delivery of ribozymes for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Vascular endothelial growth factor is essential for corpus luteum angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Therapeutic potential of inhibitory VEGF splice variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

The development and therapeutic potential of protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Update on angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Sunitinib: a newly approved small-molecule inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Drug approval triggers debate on future direction for cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Optimal locoregional treatment in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Two steps forward in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Current status of angiogenesis inhibitors combined with radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

A cancer therapy resistant to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

Relation of neovascularisation to metastasis of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.83

21 January 2018

Identifiers

DOI

10.1517/13543784.16.1.83

1 reference

15 August 2017

1 reference